Novo Nordisk files NDA for diabetes drug in Japan
The Japanese Phase III program, which included 678 patients with type 2 diabetes, was designed to obtain the indication for use of liraglutide to treat type 2 diabetes

The Japanese Phase III program, which included 678 patients with type 2 diabetes, was designed to obtain the indication for use of liraglutide to treat type 2 diabetes

Under the exclusive distribution agreement, Ferrer has gained rights to sell the tests in Germany, France, Italy, and Portugal, in addition to a current agreement signed in 2007

Prior to this agreement BioWa and Lonza entered into a strategic research collaboration agreement combining Kyowa Hakko’s Potelligent technology with Lonza’s glutamine synthetase (GS) Gene Expression System. This

DatCard’s patent is directed to systems that distribute and record digital imaging and communications in medicine (DICOM) medical image data onto CDs or DVDs that can be read

Penwest has begun dosing in a Phase Ia clinical trial of A0001, a 2nd generation coenzyme Q10 (CoQ10) analog. It differs from CoQ10 in that it possesses more

Under the deal, Amsterdam Molecular Therapeutics (AMT) will receive the exclusive commercial rights to the final product. The combination of this gene with AMT’s proprietary adeno-associated virus gene

Under the terms of the agreement Aslan will pay a transfer price for the bulk product which is dependent on the specified concentration of human lactoferrin product (hLF).

The new drug application (NDA) proposed the use of Genasense plus chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia. The recent submission was based on new

In the letter responding to the OncoGenex submission, the FDA stated that they agreed with the design and planned analysis proposed by OncoGenex, and that the study design

Biohellenika, the provider of cord blood stem cell banking services in Greece, will be the exclusive provider of the StemSource Cell Bank cryopreservation services in Greece. The StemSource